By Michael Irving A promising new cancer drug will soon enter phase 2 clinical trials, after finding success in animal models and preliminary human studies. Known as AMG 510, the drug targets a gene mutation that’s one of the most common causes of cancer. Errors in a gene called KRAS are responsible for up to...